#1 Clinical Trials Search in Europe

Corline Heparin Conjugate

This article discusses clinical trials investigating the use of Renaparin, a drug containing Corline Heparin Conjugate, for improving kidney graft function in patients receiving deceased-donor kidney transplants. The trials aim to assess the efficacy and safety of Renaparin in reducing ischemia-reperfusion injury and delayed graft function in transplant recipients with end-stage renal disease.

Table of Contents

What is Renaparin?

Renaparin, also known as Corline Heparin Conjugate (CHC), is a new medication being studied for its potential to improve kidney function in transplant patients[1]. It is classified as an anticoagulant solution, which means it helps prevent blood clots. Renaparin is specifically designed for use in kidney transplantation procedures.

How Does Renaparin Work?

Renaparin is a special type of medication that is applied to donor kidneys before they are transplanted into patients. It works by coating the blood vessels inside the kidney, which may help protect the organ from damage during the transplant process[1]. This protection is particularly important because it may reduce the risk of complications such as ischemia-reperfusion injury (IRI) and delayed graft function (DGF).

To explain these terms:

  • Ischemia-reperfusion injury (IRI): This is damage that can occur when blood flow is restored to an organ after a period without oxygen. In kidney transplants, this can happen when the donor kidney is reconnected to the recipient’s blood supply.
  • Delayed graft function (DGF): This refers to a situation where the transplanted kidney doesn’t start working immediately, often requiring the patient to continue dialysis for a period after the transplant.

Who Can Benefit from Renaparin?

Renaparin is being studied for use in patients with end-stage renal disease or otherwise insufficient kidney function who are receiving a kidney transplant from a deceased donor[1][2]. Specifically, the clinical trials are focusing on patients who:

  • Are between 18 and 75 years old
  • Have been on dialysis for more than two months
  • Are receiving a kidney from a deceased donor
  • Weigh between 45 and 115 kg

It’s important to note that Renaparin is still in the research phase and is not yet available as a standard treatment.

Clinical Trial Details

Renaparin is currently being studied in Phase 2 clinical trials[1][2]. These trials are designed to assess how well Renaparin works and how safe it is for patients. Here are some key details about the ongoing studies:

  • The trials last for 3 months, with an additional 9-month follow-up period
  • They are “single-blind” studies, which means that the patients don’t know whether they’ve received Renaparin or not, but the doctors do
  • The studies compare kidneys treated with Renaparin to untreated kidneys
  • The main goal is to measure kidney function 3 months after the transplant

Potential Benefits

If successful, Renaparin could offer several benefits to kidney transplant patients[1][2]:

  • Improved kidney function after transplant
  • Reduced risk of delayed graft function
  • Faster recovery and less need for dialysis after transplant
  • Potentially longer-lasting transplanted kidneys

These benefits could significantly improve the quality of life for kidney transplant recipients and increase the success rate of kidney transplants.

Safety Considerations

As with any new medication, safety is a top priority in the Renaparin clinical trials. The researchers are carefully monitoring for any side effects or complications. Some patients who should not receive Renaparin include those with[1][2]:

  • A high risk of blood clots or bleeding
  • A history of heparin-induced thrombocytopenia (a rare reaction to heparin)
  • Known fish allergies
  • Certain viral infections (HIV, hepatitis B, hepatitis C)
  • A recent history of cancer

It’s important to remember that Renaparin is still being studied, and more information about its safety and effectiveness will become available as the clinical trials progress.

Aspect Details
Study Type Phase 2, single-blind, randomized, controlled clinical trial
Drug Renaparin (containing Corline Heparin Conjugate)
Target Condition End-stage renal disease in kidney transplant recipients
Main Objective Assess effect on graft function in high-risk transplant patients
Primary Endpoint Estimated glomerular filtration rate (eGFR) at 3 months
Key Secondary Endpoints Incidence of delayed graft function, serum creatinine levels, urine output
Study Duration 3 months with additional 9-month follow-up
Patient Eligibility Adults 18-75 years, on dialysis, receiving deceased donor kidney
Treatment Arms Renaparin-treated donor kidney vs. Non-treated donor kidney

FAQ

  • What is Renaparin and how is it used in kidney transplantation? Renaparin is a solution for organ preservation containing Corline Heparin Conjugate. It is being studied for use in kidney transplantation to potentially improve graft function in patients receiving kidneys from deceased donors. The drug is applied to the donor kidney before transplantation to help protect it from damage during the transplant process.
  • Who are the potential candidates for these clinical trials? Potential candidates are adults aged 18-75 with end-stage renal disease who are on dialysis and are suitable for kidney transplantation. They must be receiving a kidney from a deceased donor that meets specific criteria. Patients must not have had a previous kidney transplant or be scheduled for multi-organ transplantation.
  • What is the main goal of these clinical trials? The main goal is to assess how Renaparin affects kidney graft function in transplant patients who are at high risk of ischemia-reperfusion injury and delayed graft function. The primary measure is the estimated glomerular filtration rate (eGFR) at 3 months after transplantation.
  • How long do the clinical trials last? The trials have an initial 3-month period to assess the primary outcome, followed by an additional 9-month follow-up period. In total, patients are monitored for 12 months after their kidney transplant.
  • What are some of the key things being measured in these trials? The trials measure several outcomes, including the incidence of delayed graft function, serum creatinine levels, estimated glomerular filtration rate (eGFR), urine output, and the proportion of patients with immediate graft function or primary non-function. They also assess the safety and tolerability of Renaparin in transplant patients.

Ongoing Clinical Trials on Corline Heparin Conjugate

Glossary

  • Renaparin: A solution for organ preservation containing Corline Heparin Conjugate, being studied to improve kidney graft function in transplant recipients.
  • Corline Heparin Conjugate: The active substance in Renaparin, designed to protect the kidney during transplantation.
  • End-stage renal disease: A condition where the kidneys no longer function well enough to meet the body's needs, typically requiring dialysis or kidney transplantation.
  • Ischemia-reperfusion injury (IRI): Damage that occurs when blood supply returns to tissue after a period of lack of oxygen, common in organ transplantation.
  • Delayed graft function (DGF): A complication in kidney transplantation where the transplanted kidney does not function immediately, often requiring dialysis in the first week after transplantation.
  • Glomerular filtration rate (GFR): A measure of how well the kidneys are filtering waste from the blood, used to assess kidney function.
  • Deceased donor: A person who has died and whose organs are donated for transplantation.
  • DBD-ECD: Donation after brain death – extended criteria donor, referring to a type of deceased organ donor.
  • DCD: Donation after circulatory death, another type of deceased organ donor.
  • Serum creatinine: A waste product in the blood that is normally filtered by the kidneys, used as an indicator of kidney function.
  • Primary non-function (PNF): A serious complication where the transplanted kidney never starts functioning.
  • Single-blind study: A type of clinical trial where the patients do not know which treatment they are receiving, but the medical staff does.

References

  1. http://clinicaltrials.eu/trial/study-on-renaparin-for-improving-kidney-function-in-transplant-patients-with-end-stage-renal-disease-from-deceased-donors/
  2. http://clinicaltrials.eu/trial/study-on-renaparin-for-improving-kidney-function-in-patients-with-end-stage-renal-disease-receiving-deceased-donor-transplants/